Wedescribe an acute eosinophilic pneumonia (AEP) patient with bronchoalveolar lavage fluid (BALF).
Introduction
Eosinophilic pneumonia has been reported as pulmonary infiltration of the lung by eosinophils that mayor maynot be accompanied by infiltration in the peripheral blood (1) . The etiology of eosinophilic pneumonia has been described by helminthic infections (2) , drugs (3), environmental exposure (4), and collagen diseases (1) . The clinical course of these diseases is chronic, and is characterized by persistent or recurrent pulmonary infiltration.
Onthe other hand, it has been reported that acute eosinophilic pneumonia (AEP) is characterized by severe hypoxemia, diffuse infiltrates and an increased cell numberof eosinophils in bronchoalveolar lavage (BAL) and/or lung biopsy specimens (5, 6). Wedescribe acute eosinophilic pneumonia with clinical features, BAL fluid (BALF) and follow-up study. Also, we measured eosinophil active cytokines [IL-3, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-5], and eosinophil cationic protein in BALF. This is the first report of measurement of cytokine contents of BALF and serum in acute eosinophilic pneumonia.
Case Report
A 21-year-old Japanese man was admitted to our hospital because of acute respiratory failure. He had no history of atopic disease or bronchial asthma. Further, his history revealed that he was indeed healthy prior to this illness. He was an athlete in college, and began to smoketwo weeksbefore admission. During this time he noticed dry cough, shortness of breath, and fever (37.4°C). He visited a physician and was diagnosed as having pneumonia, and was administered minocycline (200 mg/day). On the next day, he complained of severe dyspnea and was referred to our hospital. urinalysis were within normal limits. A room-air arterial blood gas analysis revealed apH of7.42, PaCO2 of39.7 mmHg,PaO2 of 39.6 mmHg, and a saturation of 72.5%. The calculated alveolar-arterial oxygen difference was 49.2 mmHg.Gramand acid-fast stains of the sputum were negative. Cold agglutinins were negative, and serum IgE was 207 IU/ml. The admission chest radiograph ( Fig. la) and CT scans ( Fig. lb and c Eosinophil survival (%) Fig. 2 . Neutralization experiments of serum and BALFby monoclonal antibodies against cytokines in eosinophil survival assay. Serum ( 1 0%v/v) and BALF(10% v/v) are treated with antibodies (1 Jig/ml) for 1 hour at room temperature and cultured with freshly isolated humanhealthy controls' eosinophils (2.5x 1 04) and Habri-Care medium (American type culture collection, USA) supplemented with 10% inactivated defined calf serum (Hyclone Laboratories Inc. , USA). Eosinophil viability with and without rhIL-5 was 78% and 10% in Fig. 2a and 93% and 19% in Fig. 2b , respectively. Eosinophil viability was measured on day 4. Data are presented as the mean±SEM. Monoclonal antibodies (anti-IL-3, anti-IL-5 and anti-GM-CSF) were donated by GJ. Gleich (Mayo Clinic, Rochester, MN, USA). *p<0.05 Significantly different with anti-IL-5 monoclonal antibody and without antibody. IL-3: interleukin 3 , rhIL-5 : recombinant human interleukin 5 , GM-CSF:granulocyte/ macrophage colony-stimulating factor. examined eosinophil survival assay in BALFand serum which could measure eosinophil active cytokines (IL-3 , IL-5 and GM-CSF) as reported before (7). Anti-IL-5 monoclonal antibody (mAb) significantly neutralized eosinophil survival in BALF and serum. Furthermore, the contents of IL-5 in BALFand serum by ELISA (8) were 8.22xlO2 pg/ml and 9.47xlO2 pg/ml, respectively. The content of IL-5 in normal healthy control serum was <100 pg/ml. On the 4th day after admission, a pulmonary function test revealed a mixed respiratory disorder (%VC: 50. 1%, FEV1%: 72.7%) anddecreased %DLCO(46.4%). On the 6th day after admission, methylprednisolone pulse therapy (500 mg intravenously every 1 2 hours) was initiated for 3 days. The patient improved rapidly, with normalization of his resting room-air arterial blood gas determinations within 5 days after treatment. On the 6th day after treatment, the white cell count was 6,910/jjl, with 6% bands, 35% neutrophils, 29.5% lymphocytes, 10% monocytes, and 17.5% eosinophils. On the 1 6th day after treatment, the white cell count was 6,490/jjI, with 4% bands, 57% neutrophils, 31.5% lymphocytes, 12.5% monocytes, and 3% eosinophils (Fig. 3) . Pulmonary function test on the 10th day after treatment was also revealed to be within normal limits. Bronchofiberscopy on the 15th day after treatment revealed normal endobronchial anatomy and the BALFcell number was 8.2xlO4/|il, with 76.6% macrophages, 16.4% lymphocytes, and 7% eosinophils. The contents of IL-5 in BALF and serum were <1.0xl02 pg/ml and 6.9xlO2 pg/ml, respectively. The chest radiograph and CT scans at discharge showed no infiltrate shadow. On the third week after discharge, he was asymptomatic and also had a normal chest examination and radiograph. The third month after discharge BFS revealed normal endobronchial anatomy. The cell number and differential count of BALFshowed no significant difference compared with normal subjects. The level of IL-5 in serum reduced to within the normal range.
IL-5 in Acute Eosinophilic Pneumonia

Discussion
Wedescribe a patient with acute respiratory distress characterized by a slight fever, severe hypoxemia, dry cough, diffuse pulmonary infiltrates and bilateral pleural effusions, increased number of eosinophils in bronchoalveolar lavage, no evidence of infection, no history of atopic disease, and complete resolution of all abnormalities after the administration of corticosteroid pulse therapy, and no recurrence. Allen and colleagues previously reported (6) that acute eosinophilic pneumonia (AEP) is distinct from chronic eosinophilic pneumonia (CEP).
Chronic eosinophilic pneumonia is an idiopathic syndrome characterized by pulmonary and peripheral blood eosinophilia infiltrates on radiography, and symptoms last longer than two weeks. Typically it affects middle-aged, atopic women. The patients with CEPpresent symptomsthat have lasted an average of 7.7 months. The present case differed from CEPin several ways. First, he did not fit the demographic picture. Secondly, he had symptoms for only one day before respiratory failure developed. Furthermore, our patient was febrile, and had a low partial pressure of oxygen. Thirdly, he neither required prolonged corticosteroid therapy nor had evidence of recurrent disease during the follow-up period after therapy. The distinguishing feature ofAEP is that it is short, less than a week, and the condition progresses rapidly to acute respiratory failure. All AEPpatients are reported to have respiratory distress, tachypnea, and pronounced hypoxemia (PaO2: 60 mmHg) and someone required mechanical ventilation (6). The pneumonia resolves within 1-8 days with steroid therapy and no recurrences have been reported (5, 9, 10).
The pathophysiological mechanism of AEPremains obscure; however, it may be due to a hypersensitivity in the lung. The production ofIL-5 presumably derived from CD4+ cells in the lung seems to be muchhigher than that in serum, because BALFwas diluted with saline (50 ml x 3 times washing). Elevated IL-5 in the lung may initiate recruitment of eosinophils (1 1), increase eosinophil survival (12), and release chemical mediators from eosinophils (13) which increases the permeability of the vessels. Elevated IL-5 in BALFwas immediately reduced by the treatment. However, it is interesting that the levels of IL-5 in the serum remain high before and after treatment. These data suggest that IL-5 producing cells are still present after the treatment. In the future it will be interesting to study the mechanism for eosinophil migration from the peripheral blood stream to lung. Finally, it is important to distinguish between acute eosinophilic and infectious pneumonias, because of the differing treatments. When the diagnosis ofAEP is not confirmed,.BALF should be performed early.
